Edition:
United Kingdom

Infant Bacterial Therapeutics AB (IBTb.ST)

IBTb.ST on Stockholm Stock Exchange

182.00SEK
20 Mar 2019
Change (% chg)

-- (--)
Prev Close
182.00kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
19,149
52-wk High
207.00kr
52-wk Low
110.50kr

Latest Key Developments (Source: Significant Developments)

Infant Bacterial Therapeutics AB Announces First Distribution Agreement
Tuesday, 5 Mar 2019 

March 6 (Reuters) - INFANT BACTERIAL THERAPEUTICS AB ::ANNOUNCED ON TUESDAY FIRST DISTRIBUTION AGREEMENT.SIGNED FIRST DISTRIBUTION AGREEMENT FOR IBP-9414 WITH MEGAPHARM LTD. FOR THE ISRAELI MARKET AND THE PALESTINIAN AUTHORITY'S TERRITORIES.AGREEMENT GIVES MEGAPHARM EXCLUSIVE RIGHTS TO MARKET AND SELL THE PRODUCT.MEGAPHARM TO HANDLE REGISTRATION, PRICE NEGOTIATIONS, MANAGE MARKETING AND ALL PRACTICALITIES.CO TO ESTABLISH A DISTRIBUTION AGREEMENT IN ORDER TO OBTAIN A LARGER SHARE OF FUTURE SALES REVENUE.CO'S SHARE TO ACCOUNT FOR 70 PCT OF REVENUES.  Full Article

Infant Bacterial Therapeutics: Phase III Study Protocol Is Modified After Meeting With FDA
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Infant Bacterial Therapeutics AB ::REG-THE PHASE III STUDY PROTOCOL IS MODIFIED AFTER IBT’S MEETING WITH THE FDA.PHASE III STUDY PROTOCOL IS MODIFIED AFTER IBT'S MEETING WITH FDA.WILL IMPROVE PROTOCOL WHICH MAY ALLOW ADDITIONAL CLAIMS SUCH AS REDUCTION IN "FEEDING INTOLERANCE".INFANT BACTERIAL THERAPEUTICS - IBT HAS CHOSEN TO MODIFY ITS PHASE III STUDY FOR PREVENTION OF NECROTIZING ENTEROCOLITIS (NEC) IN PREMATURE INFANTS.BECAUSE OF THESE CHANGES, PHASE III STUDY PROTOCOL WILL NOT START IN 2018 AS PREVIOUSLY COMMUNICATED.PHASE III STUDY PROTOCOL IS EXPECTED TO START DURING FIRST HALF OF 2019.INFANT BACTERIAL THERAPEUTICS - CO'S CURRENT FINANCIAL POSITION IS SUFFICIENT TO FINANCE IBTS CONTINUED OPERATIONS AND FINALIZE DEVELOPMENT PROGRAM.INFANT BACTERIAL THERAPEUTICS - IBT WILL IMPROVE PROTOCOL WHICH MAY ALLOW ADDITIONAL CLAIMS SUCH AS REDUCTION IN "FEEDING INTOLERANCE".  Full Article

Infant Bacterial Therapeutics Starts Listing On Nasdaq Stockholm Main Market On Sept 10
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - Infant Bacterial Therapeutics AB ::REG-INFANT BACTERIAL THERAPEUTICS HAS BEEN APPROVED FOR LISTING ON THE MAIN MARKET OF NASDAQ STOCKHOLM.LAST DAY OF TRADING ON NASDAQ FIRST NORTH PREMIER IS SCHEDULED FOR SEPTEMBER 7, 2018.FIRST DAY OF TRADING ON NASDAQ STOCKHOLM IS SCHEDULED FOR SEPTEMBER 10, 2018.  Full Article

Infant Bacterial Therapeutics Jan-March Operating Loss Slightly Widens To SEK 9.1 Million
Tuesday, 15 May 2018 

May 15 (Reuters) - INFANT BACTERIAL THERAPEUTICS AB ::JAN-MARCH OPERATING LOSS SEK 9.1 MILLION VERSUS LOSS SEK 8.6 MILLION YEAR AGO.  Full Article

Infant Bacterial Therapeutics announces capital raise
Friday, 24 Nov 2017 

Nov 24 (Reuters) - INFANT BACTERIAL THERAPEUTICS AB :REG-INFANT BACTERIAL THERAPEUTICS ANNOUNCES CAPITAL RAISE OF APPROXIMATELY SEK 545 MILLION IN TOTAL.‍DIRECTED ISSUE OF APPROXIMATELY SEK 105 MILLION HAS BEEN SUBSCRIBED FOR​.‍SUBSCRIPTION PRICE IN DIRECTED ISSUE WAS SEK 95 PER SHARE​.  Full Article

Infant Bacterial Therapeutics Q3 operating loss narrows to SEK ‍​4.6 mln
Thursday, 23 Nov 2017 

Nov 23 (Reuters) - INFANT BACTERIAL THERAPEUTICS AB :Q3 OPERATING LOSS SEK ‍​4.6 MILLION VERSUS LOSS SEK 7.9 MILLION YEAR AGO.  Full Article

BRIEF-Infant Bacterial Therapeutics AB Announces First Distribution Agreement

* SIGNED FIRST DISTRIBUTION AGREEMENT FOR IBP-9414 WITH MEGAPHARM LTD. FOR THE ISRAELI MARKET AND THE PALESTINIAN AUTHORITY'S TERRITORIES